logo

Generic

MOEHS Group.
A world reference

In a fast growing and highly competitive market, MOEHS has managed to position itself by becoming one of the main players worldwide.

THE KEY FACTORS THAT CONFIRM THIS TRACK ARE

Consolidation of a wide range of products with different therapeutic activities: from mucolytics to ß-blockers.

Continuous expansion of our list of APIs.

Optimal balance between costs and services offered.

Ability to understand the needs transmitted by customers to transfer them to our range.

Documentary and regulatory support.

Product list

Product nameCas nºTherapeutic categoryRegulatory dataPharmacopoeiaProduction site
CLOPERASTINE FENDIZOATE85187-37-7CNS Antitussive
Antihystaminic		TPJapanese
Pharmacopoeia
EDOXABAN TOSYLATE (**)1229194-11-9Oral anticoagulant ValidationDMF
EMPAGLIFLOZIN (**)864070-44-0AntidiabeticDMF
LEVOBUPIVACAINE HCl27262-48-2Local AnestheticAntiarrhythmicDMF
NORADRENALINE TARTRATE108341-18-0CardiovascularTPUSP / Ph. Eur.
REMIMAZOLAM BESYLATE (**)308242-62-8Sedation
General Anesthesia		DMF
RIMEGEPANT SULFATE (**)1374024-48-2Acute migraineDMF
RIVAROXABAN366789-02-8Oral anticoagulantCEP, DMFPh. Eur.
SITAGLIPTIN PHOSPHATE654671-77-9AntidiabeticDMFUSP / Ph. Eur.
ACEBUTOLOL HCL34381-68-5Antianginal – Antihypertensive – AntiarrhythmicCEP, EDMF, USDMFPh. Eur. 11, USP-NF-2022, JP 16M. CANTABRA & COPRIMA
AMANTADINE HCl665-66-7Antiviral -AntiparkinsonianCEP, EDMF USDMFPh. Eur. 11 USP-NF-2022, JP 16M. CATALANA
AMANTADINE SULPHATE(31377-23-8)Antiviral -AntiparkinsonianEDMFDac 2011CANTABRA
AMLODIPINE BESILATE111470-99-6Antianginal – AntihypertensiveCEP, EDMF, USDMF, JDMF, KDMFPh. Eur. 11, USP-NF-2022, JP 16M. CATALANA
ARTICAINE HCI or CARTICAINE HCI23964-57-0Local Anesthetic- AntiarrhythmicCEP, EDMF, USDMFPh. Eur. 11, USP-NF-2022BENECHIM
BISOPROLOL FUMARATE104344-23-2AntihypertensiveCEP, EDMF, USDMF, JDMF, NDPh. Eur. 11, USP-NF-2022, JP 16M. CATALANA
BUPIVACAINE HYDROCHLORIDE73360-54-0Local Anesthetic AntiarrhythmicCEP, EDMF, USDMF, NDPh. Eur. 11, USP-NF-2022M. CATALANA
BUTALBITAL(1953-33-9)Hypnotic - SedativeDMF Type IIUSPCFB
CARBOCYSTEINE638-23-3MucolyticCEP, EDMF, JDMFPh. Eur. 11, JP 16M. CATALANA & M. BCN
CARBOCYSTEINE LYSINE SALT151756-26-2Mucolytic EDMFIn houseM. BCN
CARVEDILOL72956-09-3AntihypertensiveCEP, EDMF, USDMF, JDMF, KDMF, NDPh. Eur. 11, USP-NF-2022M. CATALANA & COPRIMA
CELIPROLOL HCI57470-78-7Antianginal- AntihypertensiveCEP, EDMF, JDMFPh. Eur. 11COPRIMA
CHLORALHYDRATE302-17-0Hypnotic - SedativeTPPh. Eur., USPCFB
CHOLINE FENOFIBRATE856676-23-8AntihyperlipidemicUSDMFIn houseCOPRIMA
CINCHOPHEN132-60-5Analgesic - antipyreticASMF (CTD)Ph. Eur.CFB
DEXMEDETOMIDINE HCL145108-58-3SedativeDMFUSP-NF-2022NORCHIM & IBERICA
DOMIPHEN BROMIDE538-71-6DisinfectantTPBPCFB
DOXAZOSIN MESYLATE77883-43-3AntihypertensiveCEPPh. Eur.CFB
DULOXETINE HCL136434-34-9AntidepressantCEP, EDMF, USDMF, KDMFPh. Eur. 11, USP-NF-2022M. CANTABRA & M. BCN
FENOFIBRATE49562-28-9AntihyperlipidemicCEP, EDMF, USDMF, NDPh. Eur. 11, USP-NF-2022COPRIMA
LIDOCAINE BASE137-58-06Local Anesthetic-AntiarrhythmicCEP, EDMF, USDMF, JDMFPh. Eur. 11 USP-NF-2022, JP 16CATALANA & BCN
LIDOCAINE HCI6108-05-0Local Anesthetic-AntiarrhythmicCEP, EDMF, USDMF, JDMFPh. Eur. 11, USP-NF-2022M. CATALANA & M. BCN
MAGNESIUM LACTATE DIHYDRATE18917-93-6Magnesium SupplementEDMF, NDPh. Eur. 11CANTABRA
MEBEVERINE HCl2753-45-9AntispasmodicEDMF, NDPh. Eur. 11, BP 2013BENECHIM
MEPIVACAINE HYDROCHLORIDE1722-62-9Local Anesthetic-AntiarrhythmicCEP, EDMF, USDMFPh. Eur. 11, USP-NF-2022, JP 16M. CATALANA
METHENAMINE HIPPURATE5714-73-8Antibacterial (urinary)DMF Type IIUSPCFB
METOPROLOL SUCCINATE98418-47-4AntihypertensiveCEP, EDMF USDMFPh. Eur. 11 USP-NF-2022CATALANA & BENECHIM
METOPROLOL TARTRATE 56392-17-7AntihypertensiveCEP, EDMF USDMF, JDMFPh. Eur. 11 USP-NF-2022, JP 16 M. CATALANA
N-ACETYLCYSTEINE616-91-1MucolyticCEP, EDMF, USDMF, NDPh. Eur. 11, USP-NF-2022M. CATALANA
NIFEDIPINE21829-25-4Antianginal-AntihypertensiveCEP, EDMF, USDMF, JDMFPh. Eur. 11, USP-NF-2022, JP 16M. CATALANA
NIFUROXAZIDE965-52-6AntidiarrhealEDMF, NDPh. Eur. 11COPRIMA
NIKETHAMIDE59-26-7Respiratory analepticASMF (CTD)Ph. Eur.CFB
PANTOPRAZOLE SODIUM164579-32-2AntiulcerativeCEP, EDMF, USDMF, NDPh. Eur. 11, USP-NF-2022M. CANTABRA
PENTOBARBITAL76-74-4Anesthetic - Euthanasia - Hypnotic - SedativeASMF (CTD)Ph. Eur.CFB
PENTOBARBITAL SODIUM57-33-0Anesthetic - Euthanasia - Hypnotic - SedativeCEPPh. Eur., USPCFB
PHENOBARBITAL50-06-6Anticonvulsant - Hypnotic - SedativeCEPPh. Eur., USPCFB
PHENOBARBITAL SODIUM57-30-7Anticonvulsant - Hypnotic - Sedative-Ph. Eur., USPCFB
PHENTERMINE HCL1197-21-3Appetite suppressantDMF Type IIUSPCFB
PICLOXIDINE DIHYDROCHLORIDE19803-62-4Antiseptic (eye drops)ASMF (CTD)Ph. Eur.CFB
PRILOCAINE BASE721-50-6Local AnestheticEDMF, USDMFPh. Eur.11, USP-NF-2022BENECHIM
PRILOCAINE HCL1786-81-8Local Anesthetic-AntiarrhythmicEDMF, USDMFPh. Eur. 11, USP-NF-2022BENECHIM
PYRANTEL EMBONATE22204-24-6AnthelminticEVMF, USVMFPh. Eur. 11, USP-NF-2022, JP 16M. CATALANA & COPRIMA
QUETIAPINE FUMARATE111974-72-2AntipsychoticCEP, EDMF, USDMF, KDMFPh. Eur. 11, USP-NF-2022M. CANTABRA
RABEPRAZOLE SODIUM117976-90-6AntiulcerativeCEP, EDMF, USDMF, NDPh. Eur. 11M. CATALANA
ROPIVACAINE HCL132112-35-7Local AnestheticUSDMFPh. Eur. 11, USP-NF-2022BENECHIM
SECOBARBITAL SODIUM309-43-3Hypnotic - SedativeASMF (CTD)BP 93CFB
SITAGLIPTIN HCL862156-92-1AntidiabeticEDMFin houseBENECHIM
SOTALOL HCL959-24-0Antianginal-AntihypertensiveCEP, EDMF, USDMF, NDPh. Eur. 11, USP-NF-2022M. CATALANA
SUMATRIPTAN BASE103628-46-2AntimigraineUSDMFUSP-NF-2022M. CATALANA
SUMATRIPTAN SUCCINATE103628-48-4AntimigraineEDMF, USDMF, JDMFPh. Eur. 11, USP-NF-2022M. CATALANA
TAMOXIFEN CITRATE54965-24-1Antiestrogen - Antineoplastic (hormonal)CEP, ASMF (CTD)Ph. Eur., USD, Ph. Jap.CFB
TERAZOSIN HCL DIHYDRATE70024-40-7AntihypertensiveCEPPh. Eur.CFB
THIOPENTAL SODIUM & SODIUM CARBONATE STERILE71-73-8Anesthetic (intravenous) - NarcoticCEPPh. Eur.CFB
TRIMEBUTINE MALEATE34140-59-5AntispasmodicCEP, EDMF, NDPh. Eur. 11, JP 16M. CATALANA & M. CANTABRA
VENLAFAXINE HCI99300-78-4AntidepressantCEP, EDMF, USDMFPh. Eur. 11, USP-NF-2022M .CANTABRA

VILDAGLIPTIN

274901-16-5

Antidiabetic

DMF

Ph. Eur. 11

BCN
XYLOMETAZOLINE HCL1218-35-5Decongestant – Rhinological therapeutic - VasoconstrictorCEPPh. Eur.CFB
4(6)-PROPYL-2-
THIOURACIL		51-52-5Antihyper thyroidASMF (CTD), DMF Type IIPh. Eur., USPCFB

Products in the final phase of development

Product nameCAS N°Therapeutic categoryAvailabilityRegulatory dataPharmacopoeia
EDOXABAN (**)1229194-11-9Oral anticoagulantValidation batchesDMF
EMPAGLIFLOZIN (**)864070-44-0AntidiabeticValidation batchesDMF
LEVOBUPIVACAINE HCL (**)27262-48-2Local Anesthetic-AntiarrhythmicValidation batchesTP
REMIMAZOLAM (**)308242-62-8SedativeLaboratory batchesUS-DMF
RIVAROXABAN (**)366789-02-8Antibleeding agentValidation batchesDMFPh. Eur.
SITAGLIPTIN HCL (**)862156-92-1AntidiabeticValidation batchesDMF
SITAGLIPTIN PHOSPHATE (**)654671-77-9AntidiabeticValidation batchesDMFUSP / Ph. Eur.
VILDAGLIPTIN (**)274901-16-5AntidiabeticValidation batchesDMF

(**) Moehs is working on this compound with experimental aims, exclusively directed to obtain market authorizations of our customers’ generic medicines. We don’t intend to make any activity against any valid patent protection, as well as we will not take charge of third party actions made with the provided compound and without our knowledge against this protection.

See our PIPELINE products
logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.